Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art
Pharmacological Reports · 2025
DOI: 10.1007/s43440-025-00697-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Dariusz Łaszczych und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University in Torun, Jagiellońska 13, 85-067, Bydgoszcz, Poland. 301030@stud.umk.pl. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, gamma-Aminobutyric Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes (T1D) is an autoimmune disease that leads to the progressive destruction of insulin-producing β cells, resulting in lifelong insulin dependence and a range of severe complications. Beyond conventional glycemic control, innovative therapeutic strategies are needed to address the underlying disease mechanisms. Recent research has highlighted gamma-aminobutyric acid (GABA) as a promising therapeutic target for T1D due to its dual role in modulating both β cell survival and immune response within pancreatic islets. GABA signaling supports β cell regeneration, inhibits α cell hyperactivity, and promotes α-to-β cell transdifferentiation, contributing to improved islet function. Moreover, GABA's influence extends to mitigating T1D complications, including nephropathy, neuropathy, and retinopathy, as well as regulating central nervous system pathways involved in glucose metabolism. This review consolidates the latest advances in GABA-related T1D therapies, covering animal preclinical and human clinical studies and examining the therapeutic potential of GABA receptor modulation, combination therapies, and dietary interventions. Emphasis is placed on the translational potential of GABA-based approaches to enhance β cell viability and counteract autoimmune processes in T1D. Our findings underscore the therapeutic promise of GABA signaling modulation as a novel approach for T1D treatment and encourage further investigation into this pathway's role in comprehensive diabetes management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University in Torun, Jagiellońska 13, 85-067, Bydgoszcz, Poland. 301030@stud.umk.pl.
- Bielanski Hospital, Cegłowska 80, Warsaw, 01-809, Poland.
- Faculty of Pharmaceutical Sciences, Medical University of Silesia in Katowice, Jedności 8, Sosnowiec, 41-200, Poland.
- Ziko Pharmacy, Plebiscytowa 39, Katowice, Poland.
ORCID-Profile: Dariusz Łaszczych, Aleksandra Czernicka
Zitieren
APA
Łaszczych, D., Czernicka, A., & Łaszczych, K. (2025). Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art. Pharmacological Reports. https://doi.org/10.1007/s43440-025-00697-7
Vancouver
Łaszczych D, Czernicka A, Łaszczych K. Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art. Pharmacological Reports. 2025. doi:10.1007/s43440-025-00697-7
BibTeX
@article{aszczych2025,
author = {Łaszczych, Dariusz and Czernicka, Aleksandra and Łaszczych, Katarzyna},
title = {Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art},
journal = {Pharmacological Reports},
year = {2025},
doi = {10.1007/s43440-025-00697-7}
}
EUVIMED